Single Sevikar : Combination Therapy for the Treatment of Hypertension
|
|
- Gary Christian Cooper
- 5 years ago
- Views:
Transcription
1 HYPERTENSION REVIEW Single Sevikar : Combination Therapy for the Treatment of Hypertension Eduardo Pimenta, Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine Recieved 11/8/2009, Reviewed 18/8/2009, Accepted 24/8/2009 Keywords: adherence, blood pressure, hypertension, treatment DOI: / apjcm ABSTRACT Hypertension is one of the most important modifiable risk factor for cardiovascular morbidity and mortality and is highly prevalent. Recent guidelines and advisory statements have recommended lower thresholds and goals for patients with hypertension. However, approximately two-thirds of hypertensive patients do not achieve the goals. Poor adherence to anti-hypertensive medication regimens is a common cause of the practice-outcome gap. Monotherapy is also associated with difficulty to control blood pressure (BP) as most of hypertensive patients require 2 or more antihypertensive agents to effectively reduce BP. Therefore, current guidelines have recommended the use of combination therapy early in the management of hypertension or as first-line treatment. Fixed-dose combinations offer many advantages, such as convenience of use and fewer adverse events. Blockage of two or more BP regulatory systems also provides a more effective and physiologic BP reduction. Similar to other combinations, fixed-dose combination tablets containing dihydropyridine calcium channel blockers and angiotensin receptor blockers bring together two distinct and complementary mechanisms of action. CORRESPONDENCE Eduardo Pimenta, Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine, Greenslopes and Princess Alexandra Hospitals, Brisbane, QLD, Australia. e.pimenta@uq.edu.au INTRODUCTION Hypertension remains the leading cause of mortality and the third largest cause of disability in both developed and developing countries. 1,2 Worldwide, 7.6 million premature deaths, 54% of stroke and 47% of ischemic heart disease were attributed to high blood pressure (BP) in Overall, 26.4% of the adult population in 2000 had hypertension and 29.2% were projected to have this disease by The number of adults with hypertension in 2025 was predicted to as many as 1.5 billion people worldwide. 4 Significant cardiovascular (CV) risk reduction can be achieved with BP reduction. 4,5 Observational studies have shown that mortality from ischemic heart disease and stroke in persons 40 to 89 years of age increases in log linear fashion with increases in both systolic (SBP) and diastolic BP (DBP). 6 For each increase in SBP of 20 mmhg or in DBP of 10 mmhg over the entire range from 115/75 mmhg, there is a twofold increase in mortality related to coronary artery disease and stroke. BP control is the most important single issue in the management of hypertension and is rarely achieved with one drug. Although the awareness and control of hypertension have increased, approximately two-thirds of patients do not achieve the goal of <140/90 mmhg. Approximately 65% of hypertensive patients need >2 antihypertensive agents to achieve BP control. For example, in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) 7 and in the Losartan Intervention For Endpoint (LIFE) 8 trials, >70% and >90%, respectively, required >2 antihypertensive agents to achieve goal BP (<140/90 mmhg). Based on clinical trials, recent guidelines have recommended the use of combination therapy early in the management of hypertension in patients with comorbidities that require prompt BP reduction or as first-line treatment (for persons with BP >20/10 mmhg above goal). 9,10 Importance of Adherence Patient adherence is the ability and willingness of an individual patient to take medication as prescribed, complete recommended tests and consultations, follow health-related advice, and attend scheduled clinic appointments. 11 Poor adherence to medication regimens contributes to the practice-outcome gap, in which clinical guidelines are implemented but expected benefits are not realized. Adherence rates are higher in patients with acute conditions. However, chronic conditions, such as hypertension, have low adherence rates. Clinical trials report average adherence rates of only 43 to 78% among patients receiving treatment for chronic conditions. 12,13 ISSN
2 SINGLE SEVIKAR : COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION Poor adherence to the antihypertensive treatment can be partially explained due to the absence or few symptoms related to hypertension, side effects of medications and complexity of treatment, such as multiple medications. 14 Adherence rate is inversely related to the number of drugs given. For example, patients are more adherent when they take a combination as a single tablet than if they are given the same drugs as two separate pills, even when dosed once daily. 15 A meta-analysis of 9 studies with different diseases compared fixeddose combinations versus free-drug components of the regimen separately. Fixed-dose combinations improved the adherence rate by 26% compared with free-drug component regimens. A subgroup analysis of the 4 studies done with hypertensive patients showed that fixed-dose combinations decreased nonadherence to treatment by 24% compared with free-drug combinations. 16 Complexity of the dosing regimen/number of drugs is also related to patient adherence, i.e. there is a clear inverse relationship between complexity of the treatment and adherence. For example, among 198 Canadian hypertensives randomized to diltiazem twice-daily compared to amlodipine once-daily, those on the oncedaily regimen took the medication more regularly than those on the twice-daily dosing. 17 Role of Fixed-Dosed Combination Therapy in the Treatment of Hypertension Fixed-dose combination therapy is an efficacious, safe and costeffective method for decreasing BP in most patients with essential hypertension. 18 Fixed-dose combinations offer many advantages such as increased compliance, convenience of use, additive or synergistic effects, and reduction of adverse events. As many pathophysiologic factors contribute to high BP, the combination of agents with different (and complementary) mechanisms of action provides more complete blockage of pressor mechanisms with less activation of counter-regulatory mechanisms. Combining two antihypertensive agents with complementary mechanisms of action produces significantly greater BP reduction than either of the components as monotherapy Fixed-dose combinations also increase adherence to antihypertensive treatment. For example, adherence to a fixed-dose combination of the calcium channel blocker (CCB) amlodipine with the angiotensin converting-enzyme (ACE) inhibitor benazepril has been compared to adherence to free-dose combination therapy. Hypertensive subjects receiving once-daily, single-capsule, fixeddose combination of amlodipine/benazepril demonstrated significantly greater adherence than subjects receiving an ACE and a CCB as separate components (80.8 vs. 73.8%, respectively). 22 The average annual cost of CV-related care per subject was also significantly lower in hypertensive patients receiving the fixed-dose. Combinations with ACE inhibitors- or angiotensin receptor blockers (ARBs) and thiazide diuretics are the most commonly used fixeddose combination because of an additive effect on BP reduction related to complementary mechanisms of action of the components and the favorable vascular, metabolic, cardiac and renoprotective effects of the ACE inhibitors and ARBs. 9,23,24 Randomized controlled clinical trials that compared the combination versus monotherapy with either ACE inhibitor or HCTZ have generally demonstrated greater BP-lowering efficacy with lowdose combinations over higher-dose monotherapy with either single agent. 25,26 Appropriate combination therapy improves tolerability if one component is able to neutralize the adverse effects of the second agent. For example, the peripheral edema caused by the dihydropyridine CCB amlodipine is reduced with ARBs or ACE inhibitors In a prospective, randomized, doubleblind study 1,079 hypertensive patients were assigned to receive amlodipine/benazepril or amlodipine or nifedipine monotherapy. Although the incidence of edema was 15% in the high-dose nifedipine group and 24% in the high-dose amlodipine group, it was greatly reduced in patients treated with any dose of combination therapy (1.5% 3.8%) or lowdose CCB (4.9% 5.4%). 27 Olmesartan ARBs selectively block the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and other cell types. 30 Olmesartan lowers BP rapidly and effectively in hypertensive patients. An analysis of 7 randomized, double-blind, placebo-controlled studies compared the safety and efficacy of olmesartan monotherapy to placebo in patients with essential hypertension. 31 Olmesartan produced dose-dependent BP reductions in both DBP and SBP within 1 week of initiating treatment, and the response was nearly maximal within 2 weeks. Olmesartan reduces BP more effectively than other ARBs at traditionally recommended starting doses. 32 In a multicenter, randomized, double-blind trial, 588 patients received once-a-day therapy with the recommended starting doses of losartan, valsartan and irbesartan. This study showed a significantly greater reduction in sitting cuff DBP at trough with olmesartan (11.5 mmhg) than with losartan, valsartan, and irbesartan (8.2, 7.9, and 9.9 mmhg, respectively, p < olmesartan vs. losartan; p < 0.05 olmesartan vs. valsartan and irbesartan). 33 The reduction in mean 24-hour SBP with olmesartan (12.5 mmhg) was significantly greater than those with losartan and valsartan (9.0 and 8.1 mmhg, respectively) and equivalent to the reduction with irbesartan (11.3 mmhg). The reduction in mean 24-hour DBP with olmesartan (8.5 mmhg) was significantly greater than reductions with losartan and valsartan (6.2 and 5.6 mmhg, respectively, p < 0.05) and showed a trend toward significance when compared to the reduction in DBP with irbesartan (7.4 mmhg; p = 0.087). Pleiotropic effects, such as vasoprotective and antiinflammatory effects, beyond BP reduction have been described with Olmesartan. In the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) study, investigators compared the antiinflammatory effects of olmesartan alone and in combination with pravastatin in patients with essential hypertension and microinflammation. 34 Olmesartan significantly reduced serum levels of tumor necrosis factor-alpha (TNF-α), high sensitivity C-reactive protein (hs-crp), monocyte chemotactic protein-1 (MCP-1), and interleukin-6 (IL-6) compared to placebo independently of BP reduction (Table 1). Treatment with pravastatin alone did not significantly alter inflammation markers. In the Multicenter Olmesartan Atherosclerosis Regression Evaluation (MORE) study, carotida intima media thickness (IMT) and plaque volume were evaluated in 165 hypertensive patients with carotid artery disease and increased CV risk. 35 Patients were randomized to receive olmesartan or atenolol for 2 years. Although both treatments reduced IMT similarly, preferential decrease in plaque volume of larger plaques was seen with olmesartan. 49
3 HEALTHCARE BULLETIN HYPERTENSION Table 1: Changes in serum concentrations of high-sensitivity C-reactive protein (hscrp), high-sensitivity tumor necrosis factor-alpha (hstnf-α) and interleukin-6 (IL-6) in patients with essential hypertension after 6 and 12 weeks of therapy with olmesartan (n = 100) or placebo (n = 99). These changes occurred despite similar reductions in BP, suggesting an antiatherosclerotic action of olmesartan that is independent of its BP lowering effect. Finally, the Vascular Improvement with Olmesartan medoxomil Study (VIOS) evaluated if olmesartan reverses abnormal remodeling of resistance vessels and has favorable effects on central hemodynamics compared to the beta blocker atenolol despite equivalent BP control. 36 Olmesartan reversed small resistance vessel remodeling virtually back to normal, while atenolol had little to no effect on the vascular wall in spite of the presence of nearly physiological BP control. Although olmesartan has favorable effects on surrogate endpoints, results of outcome trials are not yet available. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study is evaluating the effect of the ARB olmesartan medoxomil on the incidence of microalbuminuria in 4400 patients with type 2 diabetes and normoalbuminuria. 37 ROADMAP, will also assess the effects of olmesartan on fatal and non-fatal CV events. Amlodipine 6 weeks p (compared to baseline) 12 weeks p (compared to baseline) hscrp -15.1% < % <0.02 hstnf-α -8.9% < % <0.01 IL-6-14% < % <0.01 Dihydropyridine CCBs act by decreasing calcium entry to cells through the L-type calcium channel. 38 It decreases the availability of intracellular calcium in arterial smooth muscle cells and consequently prevents actin and myosin from interacting, resulting in vasodilation. 39 Furthermore, dihydropiridine CCBs also facilitate natriuresis by increasing renal blood flow, dilating afferent arterioles, and increasing glomerular filtration pressure. Amlodipine is a long-acting 3rd generation dihydropyridine CCB that is the most commonly used agent in its class for the treatment of hypertension. 40,41 Amlodipine effectively reduces BP and CV morbidity and mortality. The Valsartan Antihypertensive Long- Term Use Evaluation (VALUE) trial compared the effects of amlodipine and valsartan as first line therapy in reducing CV outcomes in hypertensive patients at high CV risk. 42 Amlodipine treatment was associated with a more prompt and larger BP reduction than valsartan treatment, particularly early in the trial when participants were on monotherapy. Amlodipine treatment also significantly reduced the incidence of nonfatal myocardial infarction compared to valsartan treatment. In the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study, the amlodipine-perindopril regimen was more effective in reducing BP and preventing CV events than the atenolol-bendroflumethiazide regimen. 43 BP was, on average, 2.7/1.9 mmhg lower in the amlodipine group than in the atenolol group during 5.7 years of follow-up and amlodipine-based treatment was superior in preventing fatal and nonfatal stroke and total CV events compared to atenolol-based treatment. Amlodipine ± perindopril was also superior in reducing procedures and all-cause mortality compared to atenolol ± bendroflumethiazide. Although amlodipine is effective in reducing BP and CV morbidity and mortality, it does not reduce heart failure. In the ALLHAT, over 40,000 high risk hypertensive patients were randomized to receive chlorthalidone, amlodipine, lisinopril or doxazosin. 44 Amlodipine was as effective as chlorthalidone in reducing the primary combined endpoint of fatal coronary heart disease or nonfatal myocardial infarction. Furthermore, amlodipine was effective in reducing end-stage renal disease and combined coronary heart disease events. However, heart failure was 38% more common in patients assigned to amlodipine than patients assigned to chlorthalidone in the absence of concomitant therapy with ACE inhibitors or ARBs in either group. There was a small but significant difference in SBP between the groups. Amlodipine is also effective in decreasing left ventricular mass in hypertensive patients. In the Effects of Amlodipine and Lisinopril on Left Ventricular Mass and Diastolic Function (ELVERA) trial, which compared amlodipine to lisinopril therapy in 166 elderly hypertensive patients, amlodipine and lisinopril reduced left ventricular mass and improved diastolic function to a similar extent after 2 years of follow-up. 45 Olmesartan-Amlodipine Combination Recent studies have demonstrated the synergism between ARBs and CCBs in vascular protection. In an experimental study, inflammatory vascular remodeling injury was induced by a polyethylene tube placed loosely around the left femoral artery of mice. 46 Those animals were subsequently treated with olmesartan monotherapy or in combination with CCBs (nifedipine, amlodipine and azelnidine) or HCTZ. The combination of olmesartan with CCB significantly inhibited neointimal formation, oxidative stress and inflamatory markers. The pharmacokinetic profile of amlodipine and olmesartan have been studied after coadministration of amlodipine besylate and olmesartan medoxomil concomitantly as separate dosage forms and together in a fixed-dose combination tablet in healthy volunteers. 47 The mean steady-state pharmacokinetics of amlodipine and olmesartan were similar when olmesartan medoxomil 40 mg/ day and amlodipine 10 mg/day were administered separately or concomitantly demonstrating that, from a pharmacokinetic perspective, the two drugs are suitable for coadministration in a fixeddose combination. The combination of olmesartan and amlodipine in a single tablet effectively reduces BP and attenuates the adverse events of the amlodipine component in patients with hypertension. In the Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure (COACH) study, 1,940 subjects with mild to severe hypertension (seated DBP ranging from 99/120 mmhg) entered in an 8-week, double-blind, multi-center, randomized, placebo controlled, parallel group, factorial study
4 SINGLE SEVIKAR : COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION The study compared BP reduction with placebo, monotherapy with amlodipine 5 or 10 mg, olmesartan medoxomil 10, 20, or 40 mg, and combination therapy with amlodipine/olmesartan medoxomil at doses of 5/10, 5/20, 5/40, 10/10, 10/20, and 10/40 mg. All combinations produced greater mean BP reductions than either drug alone. The highest dose combination, amlodipine 10 mg plus olmesartan 40 mg, reduced SBP by 28.5 mmhg and DBP by 19.4 mmhg, compared to 18.9 and 13.3 mmhg, respectively, for amlodipine alone. The proportion of patients that achieved the BP goal after 8 weeks was higher within patients that received combination therapy than those treated with monotherapy. The addition of olmesartan to amlodipine also decreased the amlodipine-related adverse effects. The frequency of edema was 36.8% in patients treated with amlodipine 10 mg monotherapy and 23.5% in those treated with amlodipine 10 mg plus olmesartan 40 mg. All combinations of amlodipine 10 mg with olmesartan demonstrated less peripheral edema than amlodipine 10 mg monotherapy. Combination of olmesartan and amlodipine is also effective in patients that remained hypertensive after amlodipine monotherapy. In a double-blind, parallel-group, multicenter study, patients with moderate to severe hypertension (mean BP at baseline 164/102 mmhg) that had failed to respond to treatment with open-label amlodipine 5 mg for 8 weeks were randomized to receive amlodipine 5 mg plus placebo or a combination of olmesartan medoxomil (10 40 mg) plus amlodipine 5 mg for a further 8 weeks. 49 Patients in whom both SBP and DBP were >140/90 mmhg at week 16 had their medication increased to olmesartan medoxomil/amlodipine 20/5 mg, 40/5 mg or 40/10 mg. More than 70% of patients on active combination therapy achieved BP goal (<140/90 mmhg or <130/80 mmhg for patients with diabetes) by week 24 and all combination regimens were well tolerated (Figure 1). Figure 1: Percentage of patients who achieved target BP (< 140/90 mmhg or < 130/80 mmhg for patients with diabetes). (Modified from Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:11 25). Moreover, the combination of olmesartan with amlodipine results in a better metabolic and anti-inflammatory effects than the combination of olmesartan with hydrochlorothiazide. The former combination significantly decreased insuline resistance and inflammatory markers such as TNF-α, hs-crp, IL-1 and IL CONCLUSIONS Combination therapy has become widely accepted by health care providers for the treatment of hypertension and is recommended by current guidelines. Fixed-dose combinations offer many advantages such as increased compliance, convenience of use, additive or synergistic effects, and reduction of adverse events. Effective combination therapies, such as olmesartan plus amlodipine, block two or more BP regulatory systems providing more effective and more physiologic BP reduction than most monotherapies. REFERENCES Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367: Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, Lancet. 2008;371: Kearney PM, Whelton M, Reynolds K, Muntner P, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005:365: Turnbull F. Blood Pressure Lowering Treatment Trialists Colaboration. Effects of different blood-pressure-lowering regimens on major CV events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362: Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4: Dahlöf B, Devereux RB, Kjeldsen SE, et al. CV morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359: Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42: Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: Murphy J, Coster G. Issues in patient compliance. Drugs. 1997;54: Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther. 2001;23: Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17: Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:
5 HEALTHCARE BULLETIN HYPERTENSION Neutel JM. Fixed combination antihypertensive therapy. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector s the kidney. 2nd ed. Philadelphia: Elsevier; 2005: Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120: Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13: Sica D. Rationale for fixed-dose combination in the treatment of hypertension: the cycle repeats. Drugs. 2002;62: Hasebe N, Kikuchi K, for the NICE Combi Study Group. Controlledrelease nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens. 2005;23: Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17: Chrysant SG. Antihypertensive effectiveness of low-dose lisinoprilhydrochlorothiazide combination. Arch Intern Med. 1994;154: Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixeddose amlodipine besylate/benazepril HCL versus comparable component based therapy. Congest Heart Fail. 2003;9: Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibitor on diabetic nephropaty. The collaborative study group. N Eng J Med. 1993;329: Weir MR, Dzau VJ. The rennin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 2001; 12:177S 181S. Chrysant SG. Antihypertensive effectiveness of low-dose lisinoprilhydrochlorothiazide combination. Arch Intern Med.1994;154: Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17: Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86: Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens. 2005;7: Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29: Ruddy MC, Kostis JB. Angiotensin II receptor antagonists. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector s the kidney. 2nd ed. Philadelphia: Elsevier; 2005: Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87:37C 43C. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18: Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3: Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110: Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;1: Smith RD, Yokoyama H, Levy PJ, et al. Non-invasive hemodynamic data refflect treatment effects on vascular remodeling. J Clin Hypertens. 2007;9: A145(abstract). Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24: Messerli FH. Evolution of calcium antagonists: past, present, and future. Clin Cardiol. 1993;26:II12 6. Prisant LM. Calcium antagonists. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector s the kidney. 2nd ed. Philadelphia: Elsevier; 2005: Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341: Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens. 2004;6: Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363: Dahlöf B, Sever PS, Poulter NR, et al. Prevention of CV events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366: ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288: Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19: Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, et al. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens. 2009;22: Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol. 2008;48: Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30: Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29: Martinez-Martin FJ, Macias-Batista A, Rodriguez-Rosas H, et al. Treatment with a combination of Olmesartan plus Amlodipine vs. Olmesartan plus Hydrochlorothiazide in hypertensive patients with metabolic syndrome increases insulin sensitivity and adiponectin and reduces inflammation markers. J Hypertens. 2008;26 (Suppl I):S331(abstract). Originally published in Clinical Medicine Therapeutics
In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationIntroduction. Eduardo Pimenta 1 Suzanne Oparil 2 REVIEW
REVIEW Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan amlodipine combination Eduardo Pimenta 1 Suzanne Oparil 2 1
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationORIGINAL ARTICLE. S Oparil 1, SG Chrysant 2, M Melino 3, J Lee 3, S Karki 3 and R Heyrman 3 1. Introduction
(2010) 24, 831 838 & 2010 Macmillan Publishers Limited All rights reserved 0950-9240/10 www.nature.com/jhh ORIGINAL ARTICLE Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationThe control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS
REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood
More informationAntihypertensive Efficacy of Combination Treatment with Olmesartan Medoxomil and Amlodipine
Clinical Medicine Reviews in Vascular Health Consise Review Antihypertensive Efficacy of Combination Treatment with Olmesartan Medoxomil and Amlodipine Michiya Igase 1, Katsuhiko Kohara 1 and Tetsuro Miki
More informationABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z
Adv Ther (212) 29(6):58 523. DOI 1.17/s12325-12-3-z ORIGINAL RESEARCH Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationThe underestimated risk of
Earn 3 CPD Points online The underestimated risk of hypertension Dr David Webb Johannesburg Introduction The high and increasing worldwide burden of hypertension is a major global health challenge. Hypertension
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationAmlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management
Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Bum-Kee Hong Yongdong Severance Hospital Yonsei University College of Medicine Rationale for Multiple-Mechanism Therapy Inadequacy
More informationClinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27
Clinical trials and clinical pharmacology 21 Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial William B.
More informationChoice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationOptimal Antihypertensive Combination Treatments
HYPERTENSION REVIEW Optimal Antihypertensive Combination Treatments Massimo Volpe, 1,2 Giuliano Tocci 2 Sami A. Omar 3 Received 14/12/2011, Reviewed 20/1/2012, Accepted 13/2/2012 Key words: Antihypertensives,Combination
More informationLowering blood pressure in 2003
UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor
More informationIn patients with severe hypertension, the shortterm
Review Paper The Risks and Benefits of Initial Irbesartan Hydrochlorothiazide Combination Therapy in Patients With Severe Hypertension Pablo Lapuerta, MD; 1 * Stanley Franklin, MD 2 The impact of delays
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationAmlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy
ORIGINAL ARTICLE Korean J Intern Med 2014;29:315-324 and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy Seung-Ah Lee 1,
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationThe Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension Focus on Recent Studies
REVIEW ARTICLE Am J Cardiovasc Drugs 2010; 10 (5): 315-320 1175-3277/10/0005-0315/$49.95/0 ª 2010 Adis Data Information BV. All rights reserved. The Role of Angiotensin Receptor Blocker and Calcium Channel
More informationIndication as per product monograph: Indicated for the treatment of mild to moderate essential hypertension.
Report on New Patented Drugs Olmetec Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drug products conducted by Board Staff for purposes of applying the
More informationFixed-dose Combination Therapy in Hypertension: Focus on Fixed-dose Combination of Amlodipine and Valsartan (Exforge )
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Fixed-dose Combination Therapy in Hypertension: Focus on Fixed-dose
More informationManagement of Hypertension
33 Paradigm Shift in Management of Hypertension SN Narasingan Abstract: High blood pressure is among the most important preventable causes of death worldwide and the treatment of hypertension is a key
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationAmlodipine/Valsartan Fixed Dose Combination: Its Role in the Treatment of Hypertension
Amlodipine/Valsartan Fixed Dose Combination: Its Role in the Treatment of Hypertension Tehreem F Butt, MBChB (UK), MRCP (UK); Bernard MY Cheung, MB BChir, PhD, FRCP A substantial number of patients with
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationWill the recent hypertension trials change the guidelines?
710891JRA0010.1177/1470320317710891Journal of the Renin-Angiotensin-Aldosterone SystemSever research-article2017 Commentary Will the recent hypertension trials change the guidelines? Journal of the Renin-Angiotensin-
More informationREDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT
REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT Vida Stankus 1, Brenda Hemmelgarn 2, Norm RC Campbell 2, Guanmin Chen 2, Finlay A McAlister 1, Ross T Tsuyuki 1 1 EPICORE Centre, Department of Medicine,
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationEfficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationEfficacy in angiotensin receptor blockade: a comparative review of data with olmesartan
Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Josep Redon, Maria Jose Fabia Key words: angiotensin receptor blocker, blood pressure, hypertension, olmesartan,
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationThe importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy
(2006) 20, 169 175 & 2006 Nature Publishing Group All rights reserved 0950-9240/06 $30.00 www.nature.com/jhh REVIEW The importance of early antihypertensive efficacy: the role of angiotensin II receptor
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationImprovement of drug adherence using single pill combinations:
Improvement of drug adherence using single pill combinations: what is the evidence? Prof. Michel Burnier Service of Nephrology and Hypertension, CHUV, Lausanne, Switzerland Potentialcauses of non-adherence
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationHypertension in the elderly
091 Hypertension in the elderly Hypertension remains widely prevalent and a significant determinant of cardiovascular risk in the elderly population. Several large controlled trials have shown the benefits
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationImpact of recent landmark clinical trials on hypertension treatment
Review: Clinical Trial Outcomes Impact of recent landmark clinical trials on hypertension treatment Clin. Invest. (2011) 1(8), 1141 1154 High blood pressure remains an important global cause of cardiovascular
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More information